IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. announced today that the company has made significant progress in advancing its lead project, bardoxolone methyl, for the treatment of chronic kidney disease (CKD). Based on encouraging results from a recently completed Phase 2a trial, the company has initiated a Phase 2b trial of this agent in patients with advanced chronic kidney disease (CKD) and Type 2 diabetes. To finance this trial, the company closed $32.0 million in the first tranche of a private financing round. Additionally, the company recently added Eric Grossman, a Nephrologist with significant drug development experience, to its team as the Vice President of Clinical Development and Medical Affairs.
